Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6093023 | Gastroenterology | 2014 | 35 Pages |
Abstract
In a prospective trial, omalizumab did not reduce symptoms of eosinophilic esophagitis or tissue eosinophil counts compared with placebo. This finding, along with observed granular deposits of IgG4, abundant IgG4-containing plasma cells, and serum levels of IgG4 reactive to specific foods, indicate that, in adults, eosinophilic esophagitis is IgG4-associated, and not an IgE-induced allergy. ClinicalTrials.gov number: NCTÂ 00123630.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Frederic Clayton, John C. Fang, Gerald J. Gleich, Alfredo J. Lucendo, Jose M. Olalla, Laura A. Vinson, Amy Lowichik, Xinjian Chen, Lyska Emerson, Kristen Cox, Molly A. O'Gorman, Kathryn A. Peterson,